News
New research on using weight loss drugs for treating alcohol use disorder
Some weight loss and diabetes drugs that use GLP-1s have been found to help people stop drinking. Channel 5's GM released a statement saying the station and its parent company require employees "to adhere to the highest ethical standards.
The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.
However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use ...
The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas ...
Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with ...
The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...
The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...
Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...
News Medical on MSN17h
GLP-1 receptor agonists improve mood and metabolic health in adults with mental illnessGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance. Revenue hit $ ...
Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results